Literature DB >> 10227443

Tumour oxygenation during fractionated radiotherapy--comparison with size-matched controls.

G Stüben1, O Thews, C Pöttgen, M Stuschke, H Sack.   

Abstract

The effect of fractionated irradiation on the oxygenation status of experimental tumours was investigated using polarographic assessment of the pO2 distribution. Since an improvement in tumour oxygenation could simply be the result of tumour shrinkage, a comparison of pO2 readings of untreated size-matched control tumours was performed. Irradiation was carried out using 6 fractions of 6 Gy applied within 11 days. A comparison of polarographic pO2 data with size-matched untreated tumours revealed a significant improvement in oxygenation after the irradiation. The median pO2 was 0.9+/-0.1 mm Hg for unirradiated tumours at a volume of 180 mm3, while the corresponding data for irradiated tumours of comparable size were 2.3+/-0.5 mm Hg on day 21 and 4.8+/-0.9 mm Hg on day 28 after start of irradiation. From these results it can be concluded that the improvement of oxygenation after fractionated irradiation is not solely the result of a reduced tumour volume.

Entities:  

Mesh:

Year:  1999        PMID: 10227443     DOI: 10.1080/028418699431636

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  3 in total

1.  Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts.

Authors:  Susan L Dalrymple; Robyn E Becker; Haoming Zhou; Theodore L DeWeese; John T Isaacs
Journal:  Prostate       Date:  2011-08-11       Impact factor: 4.104

2.  Evaluation of fractionated and repeated sonodynamic therapy by using dual frequency for murine model of breast adenocarcinoma.

Authors:  Mahboobeh Alamolhoda; Manijhe Mokhtari-Dizaji
Journal:  J Ther Ultrasound       Date:  2015-06-24

Review 3.  A review of tasquinimod in the treatment of advanced prostate cancer.

Authors:  Stuart Charles Williamson; Alice Elizabeth Hartley; Rakesh Heer
Journal:  Drug Des Devel Ther       Date:  2013-03-21       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.